Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by RiverPark Advisors LLC

RiverPark Advisors LLC lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 58.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,639 shares of the medical research company's stock after purchasing an additional 7,583 shares during the quarter. RiverPark Advisors LLC's holdings in Edwards Lifesciences were worth $1,362,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of EW. Crewe Advisors LLC bought a new stake in Edwards Lifesciences in the first quarter valued at about $28,000. First Community Trust NA bought a new stake in shares of Edwards Lifesciences in the second quarter worth about $29,000. Webster Bank N. A. bought a new stake in shares of Edwards Lifesciences in the second quarter worth about $39,000. Peoples Bank KS bought a new stake in shares of Edwards Lifesciences in the third quarter worth about $40,000. Finally, Versant Capital Management Inc increased its holdings in shares of Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company's stock worth $45,000 after acquiring an additional 326 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Trading Up 2.4 %

Shares of NYSE:EW traded up $1.60 during trading on Friday, hitting $67.76. The company had a trading volume of 7,530,072 shares, compared to its average volume of 5,248,893. The stock has a market cap of $39.96 billion, a price-to-earnings ratio of 9.78, a price-to-earnings-growth ratio of 3.81 and a beta of 1.12. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a fifty day simple moving average of $67.44 and a two-hundred day simple moving average of $76.18. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $1.57 billion. During the same quarter in the previous year, the business earned $0.59 EPS. Edwards Lifesciences's revenue was up 8.9% compared to the same quarter last year. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Insider Activity

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at $3,133,916.72. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 41,250 shares of company stock valued at $2,744,438. Company insiders own 1.29% of the company's stock.

Analyst Ratings Changes

EW has been the subject of several research reports. Piper Sandler dropped their price target on Edwards Lifesciences from $73.00 to $70.00 and set a "neutral" rating for the company in a report on Friday, October 25th. The Goldman Sachs Group reduced their price objective on shares of Edwards Lifesciences from $107.00 to $91.00 and set a "buy" rating for the company in a research report on Friday, July 26th. Evercore ISI reduced their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an "in-line" rating for the company in a research report on Tuesday, October 1st. UBS Group reduced their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a "neutral" rating for the company in a research report on Tuesday, September 10th. Finally, Baird R W cut Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 25th. Seventeen investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $75.67.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.